Moolec Science SA (MLEC) Financials

Moolec Science SA (MLEC) reported diluted earnings per share of -$0.19 for fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Moolec Science SA (MLEC) had a gross margin of 8.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

Moolec Science SA (MLEC) has a return on equity of -107.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

Moolec Science SA (MLEC) recorded an outflow of $9.5M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Moolec Science SA (MLEC) recorded an outflow of $9.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

Moolec Science SA (MLEC) had $34.8M in total assets as of fiscal year 2024, including both current and long-term assets.

Moolec Science SA (MLEC) invested $158K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Moolec Science SA (MLEC) invested $1.8M in research and development during fiscal year 2024.

Moolec Science SA (MLEC) had 38M shares outstanding as of fiscal year 2024.

Moolec Science SA (MLEC) had a current ratio of 1.69 as of fiscal year 2024, which is generally considered healthy.

Moolec Science SA (MLEC) had a liabilities-to-equity ratio of 4.10 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.

Moolec Science SA (MLEC) had a return on assets of -21.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Moolec Science SA (MLEC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $994K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Moolec Science SA (MLEC) trades at 0.2x sales, its market capitalization divided by $5.6M revenue, FY2024. The market capitalization is $994K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Moolec Science SA (MLEC) has an Altman Z-Score of -3.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Moolec Science SA (MLEC) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Moolec Science SA (MLEC) reported a net loss of $7.3M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Moolec Science SA (MLEC) reported an operating loss of $9.0M against $41K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.